Navigation Links
Positive Results from Phase II Data Show NER1006 Achieves High Quality Bowel Cleansing Efficacy
Date:10/20/2014

LONDON, October 20, 2014 /PRNewswire/ --

Norgine B.V. today announced that the Phase II study of its novel, low volume bowel preparation, NER1006, presented at the 79th Annual Scientific Meeting of the American College of Gastroenterology (ACG), Philadelphia, PA, has met its primary efficacy end point of stool weight and co-primary endpoint of cleansing success. The study demonstrated high quality bowel cleansing efficacy with NER1006 vs. MOVIPREP® in screening colonoscopy patients.[1]

(Logo: http://photos.prnewswire.com/prnh/20130829/633895-a)

The Phase II open-label, randomised study (OPT, n=240) investigated the pharmacodynamics (stool weight), clinical efficacy and tolerability of dose and taste-optimised low-volume PEG-based formulations (NER1006), after split dosing, compared with MOVIPREP®.[1] Results demonstrate that NER1006 achieved high quality bowel cleansing in screening colonoscopy patients, comparable with MOVIPREP®. Cleansing success rates were 90-100%.[1] Stool output was consistently higher with NER1006, and safety and tolerability profiles between treatments were comparable.[1] In addition, most subjects in the NER1006 arms reached clear effluent.[1]

"Effective bowel cleansing is vital to delivering a successful colonoscopy procedure. This Phase II study confirms that NER1006, a low volume preparation, is preferential for some patients and improves tolerability. We are hoping that the Phase III programme will further show the efficacy and tolerability of NER1006," commented Donna McVey, Chief Development Officer, Norgine.

Norgine has now enrolled the first patient into the first study of its Phase III programme, NOCT, a US study. The Phase III programme consists of three clinical trials: NOCT is a multicentre, randomised, parallel-group clinical trial that is expected to enrol 540 patients across two arms, MORA and DAYB are European studies to further investigate the bowel cleansing efficacy, compliance, safety, patient acceptability and tolerability of NER1006.

--------------------------------------------

References 

1. Halphen M, et al. Pharmacodynamic and clinical evaluation of low-volume polyethylene glycol based bowel cleansing solutions (NER1006) using split dosing in healthy and screening colonoscopy subjects. ACG 2014 abstract #P330 

 

See full release on http://www.norgine.com

Charlotte Andrews: Tel - +44-(0)1895-453669

Peter Martin: Tel- +44-(0)1895-453744

 

Job code: GL/COR/1014/0024

October 2014


'/>"/>
SOURCE Norgine B.V
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results
2. Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients
3. Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps
4. SALVAT Announces Positive Top-line Results from Two Phase III Studies of its Novel Otic Antibiotic/Steroid Combination Solution in the Treatment of AOMT with Tympanostomy Tubes
5. Meritage Pharma Announces Positive Results of Oral Budesonide Suspension for Treatment of Eosinophilic Esophagitis in Adolescent and Adult Patients
6. Glenmarks TRPA1 Antagonist GRC 17536 Shows Positive Data in a Proof of Concept Study
7. ROX Medical presents positive data for CONTROL-HTN resistant hypertension trial
8. Aratana Therapeutics Reports Positive Effectiveness Data from Pilot Field Study of Bupivacaine Extended-Release Injectable Suspension (AT-003)
9. Blueprint Medicines Presents Positive Data on BLU-554 for Hepatocellular Carcinoma
10. Mast Therapeutics Announces Positive Top Line Results From Phase 2 Study Of AIR001 For Pulmonary Arterial Hypertension And AIR001 Clinical Development Plan
11. Fractyl Labs Announces Positive Clinical Data for First Procedural Therapy to Treat Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... DUBLIN , Mar. 29, 2017 ... "Intraoperative Neuromonitoring (IONM) Market Size & Forecast By Type (Insource ... - 2025" report to their offering. ... The global Intraoperative ... by 2025. The intraoperative neuromonitoring market is anticipated to witness ...
(Date:3/29/2017)... March 29, 2017 Global intravenous (IV) iron and ... by 2021, growing at a CAGR of 5%. ... a doctor to treat anemia or other iron deficiencies. Oral ... the body. However, in some cases, oral administrations are not ... intravenous (IV) iron therapy comes into the picture. ...
(Date:3/29/2017)... 29, 2017 Today, CVS Health officials (NYSE: ... , Department of Public Health Director Gerd Clabaugh ... in announcing the availability of the opioid overdose-reversal medicine ... Iowa.  CVS Health has established a standing order with physicians ... to expand access to the medication in the state.   ...
Breaking Medicine Technology:
(Date:3/30/2017)... Durham, NC (PRWEB) , ... March 30, 2017 ... ... professionals, will host the live audio conference “ Preventing Hospital Readmissions Through Discharge ... April 12, 2017 at 1:00 pm ET. This conference discusses strategies to prevent ...
(Date:3/29/2017)... ... March 29, 2017 , ... In the United States alone, up ... year develop other types of metastatic brain tumors(3). Though most meningiomas are benign, metastatic ... focus on finding more effective treatment options, the San Diego Gamma Knife Center ...
(Date:3/29/2017)... ... March 30, 2017 , ... CHARM CITY RUN WELCOMES MERCY MEDICAL CENTER AS ... Medical Center will serve as the official title sponsor of the Baltimore Women’s Classic, ... 2017, thousands of women will walk or run the course around the Baltimore Inner ...
(Date:3/29/2017)... ... March 29, 2017 , ... Wells Pharmacy ... attending prescribers at the upcoming World Congress, in Hollywood Florida April 6-8, 2017. ... recognized as the visionary leader in the training of physicians, scientists, and members ...
(Date:3/29/2017)... ... 29, 2017 , ... Patients interested in receiving quick and ... Jamie Cameron, with or without a referral. The FASTBRACES system is valued for ... each patient’s case, treatment with the FASTBRACES system could be completed in 120 ...
Breaking Medicine News(10 mins):